When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRRUF - Immutep Limited: Continuing To Make The Case For Eftilagimod
Immutep Limited
2025-01-28 16:37:29 ET
Summary
Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics.
Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential.
Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials without immediate funding concerns.
Recent clinical data suggest meaningful advancements in LAG-3 therapeutics, reinforcing the investment thesis and highlighting IMMP's undervalued status.